Latest news with #TNDM
Business Insider
30-05-2025
- Business
- Business Insider
Goldman Sachs Sticks to Their Hold Rating for Tandem Diabetes Care (TNDM)
In a report released yesterday, from Goldman Sachs maintained a Hold rating on Tandem Diabetes Care (TNDM – Research Report). The company's shares closed yesterday at $21.28. Confident Investing Starts Here: In addition to Goldman Sachs, Tandem Diabetes Care also received a Hold from Wells Fargo's Larry Biegelsen in a report issued on May 28. However, on May 20, Lake Street maintained a Buy rating on Tandem Diabetes Care (NASDAQ: TNDM). TNDM market cap is currently $1.43B and has a P/E ratio of -7.60. Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNDM in relation to earlier this year. Most recently, in March 2025, Jean-Claude Kyrillos, the EVP & COO of TNDM bought 10,538.00 shares for a total of $190,948.56.
Yahoo
22-04-2025
- Business
- Yahoo
1 Volatile Stock Worth Your Attention and 2 to Keep Off Your Radar
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors. Navigating these stocks isn't easy, which is why StockStory helps you find Comfort In Chaos. Keeping that in mind, here is one volatile stock that could deliver huge gains and two best left to the gamblers. Rolling One-Year Beta: 1.68 Doubling as a hospitality services provider for hotels and resorts, The One Group Hospitality (NASDAQ:STKS) is an upscale restaurant company that operates STK Steakhouse and Kona Grill. Why Do We Think Twice About STKS? Poor same-store sales performance over the past two years indicates it's having trouble bringing new diners into its restaurants Earnings per share fell by 19.9% annually over the last five years while its revenue grew, partly because it diluted shareholders High net-debt-to-EBITDA ratio of 8× increases the risk of forced asset sales or dilutive financing if operational performance weakens At $2.79 per share, The ONE Group trades at 0.8x forward EV-to-EBITDA. Dive into our free research report to see why there are better opportunities than STKS. Rolling One-Year Beta: 1.25 With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ:TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels. Why Should You Sell TNDM? Declining pump shipments over the past two years indicate demand is soft and that the company may need to revise its strategy Revenue growth over the past five years was nullified by the company's new share issuances as its earnings per share fell by 34.7% annually Waning returns on capital from an already weak starting point displays the inefficacy of management's past and current investment decisions Tandem Diabetes's stock price of $16.50 implies a valuation ratio of 30.9x forward EV-to-EBITDA. If you're considering TNDM for your portfolio, see our FREE research report to learn more. Rolling One-Year Beta: 2.01 Headquartered in Israel, Nova (NASDAQ:NVMI) is a provider of quality control systems used in semiconductor manufacturing. Why Are We Bullish on NVMI? Impressive 24.5% annual revenue growth over the last five years indicates it's winning market share this cycle Free cash flow margin jumped by 12.3 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends Industry-leading 31.4% return on capital demonstrates management's skill in finding high-return investments Nova is trading at $174.41 per share, or 22.7x forward price-to-earnings. Is now the time to initiate a position? Find out in our full research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Axon (+711% five-year return). Find your next big winner with StockStory today for free.
